James Mullen
Net Worth
Last updated:
What is James Mullen net worth?
The estimated net worth of Mr. James Mullen is at least $2,404,367 as of 6 Sep 2025. He owns shares worth $198,853 as insider, has earned $1,017,014 from insider trading and has received compensation worth at least $1,188,500 in Reach plc and Editas Medicine, Inc..
What is the salary of James Mullen?
Mr. James Mullen salary is $485,000 per year as Chief Executive Officer & Executive Director in Reach plc. He also receives $100,500 as Chairman, Pres & Chief Executive Officer in Editas Medicine, Inc..
How old is James Mullen?
Mr. James Mullen is 54 years old, born in 1971.
What stocks does James Mullen currently own?
As insider, Mr. James Mullen owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | Chairman, Pres & Chief Executive Officer | 75,898 | $2.62 | $198,853 |
What does Editas Medicine, Inc. do?
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
James Mullen insider trading
Editas Medicine, Inc.
Mr. James Mullen has made 2 insider trades between 2018-2022, according to the Form 4 filled with the SEC. Most recently he sold 18,252 units of EDIT stock worth $491,983 on 3 Jan 2022.
The largest trade he's ever made was exercising 25,000 units of EDIT stock on 2 Mar 2021. As of 6 Sep 2025 he still owns at least 75,898 units of EDIT stock.
Reach key executives
Reach plc executives and other stock owners filed with the SEC:
- Mr. James Mullen (54) Chief Executive Officer & Executive Director